Galectin-9 expression correlates with therapeutic effect in rheumatoid arthritis

Abstract Galectin-9 (Gal-9) is a multifunctional immunomodulatory factor highly expressed in RA. This study aimed to investigate the expression of Gal-9 and its correlation with disease activity and therapeutic response in RA patients. Active RA patients were enrolled and treated with tacrolimus (TA...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jiao Sun, Yameng Sui, Yunqing Wang, Lijun Song, Dong Li, Guosheng Li, Jianwei Liu, Qiang Shu
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/e8bd913b21a242df8785e1243abd32be
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e8bd913b21a242df8785e1243abd32be
record_format	dspace
spelling	oai:doaj.org-article:e8bd913b21a242df8785e1243abd32be2021-12-02T13:34:58ZGalectin-9 expression correlates with therapeutic effect in rheumatoid arthritis10.1038/s41598-021-85152-22045-2322https://doaj.org/article/e8bd913b21a242df8785e1243abd32be2021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-85152-2https://doaj.org/toc/2045-2322Abstract Galectin-9 (Gal-9) is a multifunctional immunomodulatory factor highly expressed in RA. This study aimed to investigate the expression of Gal-9 and its correlation with disease activity and therapeutic response in RA patients. Active RA patients were enrolled and treated with tacrolimus (TAC) alone or in combination therapy for 12 weeks in a prospective cohort study. Clinical and immunological parameters were recorded at baseline and week 12. We measured Gal-9 expression in different T cell subsets and in plasma. The disease activity of RA patients decreased after treatment. At baseline, the Gal-9 expression percentage was higher in the group with severe disease than in mild or moderate groups. After treatment, the Gal-9 expression in CD3+, CD4+, CD8+ and CD4-CD8− cell subsets decreased, as well as Gal-9 mean fluorescence intensity in CD3+, CD4+ and CD8+ T cells. Similarly, plasma Gal-9 levels were lower at week 12 than at baseline. Good responders showed significantly lower Gal-9 expression on CD3+ and CD4+ T cell subsets and lower plasma Gal-9 levels than poor responders. Gal-9 expression positively correlates with disease activity in RA patients. Gal-9 can be regarded as a new biomarker for evaluating RA activity and therapeutic effect, including TAC.Jiao SunYameng SuiYunqing WangLijun SongDong LiGuosheng LiJianwei LiuQiang ShuNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Jiao Sun Yameng Sui Yunqing Wang Lijun Song Dong Li Guosheng Li Jianwei Liu Qiang Shu Galectin-9 expression correlates with therapeutic effect in rheumatoid arthritis
description	Abstract Galectin-9 (Gal-9) is a multifunctional immunomodulatory factor highly expressed in RA. This study aimed to investigate the expression of Gal-9 and its correlation with disease activity and therapeutic response in RA patients. Active RA patients were enrolled and treated with tacrolimus (TAC) alone or in combination therapy for 12 weeks in a prospective cohort study. Clinical and immunological parameters were recorded at baseline and week 12. We measured Gal-9 expression in different T cell subsets and in plasma. The disease activity of RA patients decreased after treatment. At baseline, the Gal-9 expression percentage was higher in the group with severe disease than in mild or moderate groups. After treatment, the Gal-9 expression in CD3+, CD4+, CD8+ and CD4-CD8− cell subsets decreased, as well as Gal-9 mean fluorescence intensity in CD3+, CD4+ and CD8+ T cells. Similarly, plasma Gal-9 levels were lower at week 12 than at baseline. Good responders showed significantly lower Gal-9 expression on CD3+ and CD4+ T cell subsets and lower plasma Gal-9 levels than poor responders. Gal-9 expression positively correlates with disease activity in RA patients. Gal-9 can be regarded as a new biomarker for evaluating RA activity and therapeutic effect, including TAC.
format	article
author	Jiao Sun Yameng Sui Yunqing Wang Lijun Song Dong Li Guosheng Li Jianwei Liu Qiang Shu
author_facet	Jiao Sun Yameng Sui Yunqing Wang Lijun Song Dong Li Guosheng Li Jianwei Liu Qiang Shu
author_sort	Jiao Sun
title	Galectin-9 expression correlates with therapeutic effect in rheumatoid arthritis
title_short	Galectin-9 expression correlates with therapeutic effect in rheumatoid arthritis
title_full	Galectin-9 expression correlates with therapeutic effect in rheumatoid arthritis
title_fullStr	Galectin-9 expression correlates with therapeutic effect in rheumatoid arthritis
title_full_unstemmed	Galectin-9 expression correlates with therapeutic effect in rheumatoid arthritis
title_sort	galectin-9 expression correlates with therapeutic effect in rheumatoid arthritis
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/e8bd913b21a242df8785e1243abd32be
work_keys_str_mv	AT jiaosun galectin9expressioncorrelateswiththerapeuticeffectinrheumatoidarthritis AT yamengsui galectin9expressioncorrelateswiththerapeuticeffectinrheumatoidarthritis AT yunqingwang galectin9expressioncorrelateswiththerapeuticeffectinrheumatoidarthritis AT lijunsong galectin9expressioncorrelateswiththerapeuticeffectinrheumatoidarthritis AT dongli galectin9expressioncorrelateswiththerapeuticeffectinrheumatoidarthritis AT guoshengli galectin9expressioncorrelateswiththerapeuticeffectinrheumatoidarthritis AT jianweiliu galectin9expressioncorrelateswiththerapeuticeffectinrheumatoidarthritis AT qiangshu galectin9expressioncorrelateswiththerapeuticeffectinrheumatoidarthritis
_version_	1718392768266502144

Galectin-9 expression correlates with therapeutic effect in rheumatoid arthritis

Ejemplares similares